Saturday 17 October 2026 Export BRKR’s income statement to Excel — free account

Bruker Corporation

Bruker Corporation’s revenue for fiscal 2025 (year ended December 2025) was $3.4 billion, up 2.08% from fiscal 2024. In the quarter to June 2026, revenue grew 5.15%, EPS fell 920.0%, free cash flow grew 28.6% and total debt fell 25.1%, each against the same quarter a year earlier. Dividend growth for ten consecutive years, revenue growth for five.

54.80 1.74 −3.08%

Follow BRKR

Alert me

Market cap: $8.6B
P/E: 0.0×
Fwd P/E: 55.7×
Dividend yield: 0.36%
F-score: 4/9
Altman Z: 2.43
Beneish M: −2.56
Dividend safety: 34/100

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 3.61

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	1	1	3	1	1	1	1	1	1	2	1	—

Insider Ownership 27.12%

Capital & Financial Ratios $m

Market Cap 8,610.00

Revenue 3,499.60

Net Income (64.50)

Free Cash Flow 93.90

Net Debt 1,639.90

Current Ratio 1.85

Debt/Equity 0.76

P/E ratio 0.00

Fwd P/E 55.70

P/S ratio 2.38

P/B ratio 3.48

Past 5Y EPS Growth —

This Y EPS Growth 15.94%

Next Y EPS Growth 13.51%

Next Y revenue growth 3.48%

Next 5Y EPS Growth 15.16%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 19.72%

10-year low 10-year high

P/B against its own 10 years 10.84%

10-year low 10-year high

EV/Sales against its own 10 years 37.15%

10-year low 10-year high

EV/FCF against its own 10 years 88.24%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate 0.20

Annual Dividend Yield 0.36%

	total	individual payouts
2028	Powerpack
2027	Powerpack
2026	0.33	0.05 0.05 0.05
2025	0.20	0.05 0.05 0.05 0.05
2024	0.20	0.05 0.05 0.05 0.05
2023	0.20	0.05 0.05 0.05 0.05
2022	0.20	0.05 0.05 0.05 0.05
2021	0.16	0.04 0.04 0.04 0.04
2020	0.16	0.04 0.04 0.04 0.04
2019	0.16	0.04 0.04 0.04 0.04
2018	0.16	0.04 0.04 0.04 0.04
2017	0.16	0.04 0.04 0.04 0.04
2016	0.16	0.04 0.04 0.04 0.04

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	488	183	299	185
Receivables	492	566	545	546
Inventory	968	1,068	1,095	1,120
Other	216	237	274	374
	2,164	2,053	2,213	2,225

	2023	2024	2025	Q'26
Payables	203	234	216	200
ST’ Debt	121	33	17	10
Other	478	577	605	550
	1,202	1,281	1,279	1,205

Compound Annual Growth %

	10y	5y	3y
Sales	7.79%	11.57%	10.74%
Cash Flow	(5.22%)	(16.59%)	(21.23%)
Earnings	0.00%	0.00%	0.00%
Book Value	12.93%	20.48%	30.01%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	823	839	—	—	—
’25	801	797	861	977	3,437
’24	722	801	864	980	3,366
’23	685	682	743	854	2,965
’22	595	588	639	708	2,531
’21	555	571	609	683	2,418
’20	424	425	511	628	1,988

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	71	(77)	—	—	—
’25	65	(127)	(33)	230	134
’24	22	1	38	190	251
’23	88	13	44	206	350
’22	78	(44)	70	172	274
’21	98	22	24	139	282
’20	35	12	82	203	332

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	47	(106)	—	—	—
’25	39	(149)	(54)	207	43
’24	0	(23)	6	153	136
’23	73	(10)	17	163	243
’22	72	(61)	12	137	159
’21	75	1	9	111	195
’20	5	(8)	65	174	235

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	0.02	(0.41)	—	—	—
’25	0.11	0.05	(0.41)	0.10	(0.15)
’24	0.35	0.05	0.27	0.09	0.76
’23	0.52	0.39	0.60	1.41	2.90
’22	0.41	0.33	0.59	0.66	1.99
’21	0.37	0.38	0.57	0.50	1.81
’20	0.07	0.16	0.35	0.45	1.02

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	19.59	21.20	26.10	28.02	30.78	53.06	48.42	53.79	48.07	28.53	Analyst estimates 2026–2028 Powerpack
	High	29.85	36.53	36.49	52.23	55.87	92.35	83.69	84.84	94.86	64.64
People
People	Employees	6,000	6,200	6,870	7,230	7,400	7,765	8,525	9,707	11,396	11,085
	Revenue/emp, $m	0.27	0.28	0.28	0.29	0.27	0.31	0.30	0.31	0.30	0.31
Income, $m
Income, $m	Revenue	1,611	1,766	1,896	2,073	1,988	2,418	2,531	2,965	3,366	3,437
	Gross margin, %	46.25	46.21	47.48	48.02	47.29	50.03	51.59	51.05	49.00	45.91
	EBT	178	198	245	280	226	394	414	544	207	22
	EBT margin, %	11.02	11.20	12.91	13.53	11.36	16.28	16.36	18.36	6.15	0.64
	Net income	155	80	181	198	161	281	299	429	114	(8)
	Depreciation	54	64	65	76	80	89	89	115	184	220
Per share, $
Per share, $	Revenue	9.98	11.17	12.14	13.35	12.96	15.97	17.03	20.25	22.59	22.64
	Earnings	0.95	0.50	1.15	1.27	1.03	1.83	2.00	2.92	0.76	(0.15)
	Cash flow	0.81	0.98	1.53	1.38	2.17	1.87	1.85	2.39	1.69	0.88
	Capex	(0.22)	(0.20)	(0.31)	(0.40)	(0.63)	(0.58)	(0.78)	(0.73)	(0.77)	(0.60)
	Free cash flow	0.59	0.77	1.22	0.98	1.53	1.29	1.07	1.66	0.91	0.29
	Book value	4.29	4.64	5.79	5.91	6.35	7.16	7.58	9.53	12.06	16.29
	Shares, m	161	158	156	155	153	151	149	146	149	152
Valuation, ×
Valuation, ×	P/E	22.72	69.04	25.89	39.82	52.55	45.85	34.54	24.76	77.13	0.00
	P/S	2.16	3.09	2.45	3.82	4.18	5.25	4.06	3.57	2.59	2.08
	P/B	5.03	7.44	5.14	8.63	8.52	11.71	9.12	7.59	4.86	2.89
	EV/Sales	2.11	3.08	2.46	3.88	4.23	5.32	4.28	3.84	3.16	2.54
	EV/FCF	28.38	36.97	21.64	45.62	32.37	58.47	58.93	42.45	66.20	128.07
Cash, $m
Cash, $m	Operating cash flow	131	154	240	213	332	282	274	350	251	134
	Capex	(36)	(32)	(49)	(62)	(97)	(87)	(115)	(107)	(115)	(91)
	Free cash flow	95	122	191	151	235	195	159	243	136	43
Balance, $m
Balance, $m	Working capital	751	834	705	1,151	1,133	1,533	1,199	962	772	933
	Total debt	412	416	341	813	845	1,334	1,219	1,282	2,094	1,869
	Net debt	(89)	(24)	19	128	113	166	574	793	1,911	1,570
	Shareholders’ equity	693	734	905	917	974	1,085	1,126	1,395	1,797	2,474
Returns, %
Returns, %	ROA	8.68	4.18	8.82	8.05	5.42	8.27	8.17	10.87	2.25	(0.37)
	ROIC	18.80	19.32	17.75	17.99	14.28	20.66	15.91	12.48	4.27	1.05
	ROE	21.54	11.02	21.93	21.64	16.69	26.92	26.84	33.90	7.09	(1.05)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
PEN Penumbra, Inc.	$12.7B	78.4×	63.5×	+14.90% (above 0%: growing)	−24.79% (below 0%: shrinking)	+10.81% (above 0%: growing)	67.93%	10.52%	Compare
SNN Smith & Nephew SNATS, Inc.	$12.2B	35.4×	18.6×	+7.99% (above 0%: growing)	−14.23% (below 0%: shrinking)	+293.94% (above 0%: growing)	69.42%	0.00%	Compare
GMED Globus Medical, Inc.	$10.6B	19.3×	20.3×	+5.94% (above 0%: growing)	−25.33% (below 0%: shrinking)	+571.30% (above 0%: growing)	69.42%	23.10%	Compare
BIO.B Bio-Rad Laboratories, Inc.	$10.3B	43.7×	—	−0.09% (below 0%: shrinking)	+19.02% (above 0%: growing)	−6.06% (below 0%: shrinking)	53.12%	11.15%	Compare
GKOS Glaukos Corporation	$9.8B	— (loss-making)	— (loss-making)	+49.54% (above 0%: growing)	n/m	+211.83% (above 0%: growing)	81.67%	(9.30%)	Compare
BIO Bio-Rad Laboratories, Inc.	$9.8B	42.5×	35.4×	−0.09% (below 0%: shrinking)	+19.02% (above 0%: growing)	−6.06% (below 0%: shrinking)	53.12%	11.15%	Compare
PODD Insulet Corporation	$9.6B	26.4×	24.7×	+23.51% (above 0%: growing)	+328.13% (above 0%: growing)	−70.51% (below 0%: shrinking)	70.18%	16.18%	Compare
BRKR Bruker Corporation	$8.6B	— (loss-making)	55.7×	+5.15% (above 0%: growing)	n/m	+28.63% (above 0%: growing)	49.61%	(7.79%)
HAE Haemonetics Corporation	$5.5B	57.7×	18.0×	+5.60% (above 0%: growing)	+2.86% (above 0%: growing)	+220.38% (above 0%: growing)	59.76%	16.93%	Compare
Median of peers	$10.0B	42.5×	22.5×	+6.97%	+2.86%	+111.32%	68.68%	11.15%

All 149 Medical Devices stocks →

Bruker Corporation (BRKR) key facts

Strength: Bruker Corporation’s revenue for fiscal 2025 (year ended December 2025) was $3.4 billion, up 2.08% from fiscal 2024.
Bruker Corporation (BRKR) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, BRKR traded at $54.80, a market capitalization of $8.6 billion.
Bruker Corporation pays an annual dividend of $0.20 per share, a yield of 0.36%.
Return on equity was −1.05% and debt-to-equity 0.76.
Its Piotroski F-score is 4 out of 9 and its Altman Z-score is 2.43 (grey zone) for fiscal 2025.